Seres Therapeutics Dividend
Dividend criteria checks 0/6
Seres Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.8% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$0.75 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Mar 23
Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
Jan 30Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop
Dec 18Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop
Aug 31Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?
Aug 09Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?
Dec 28Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)
Sep 01Seres Therapeutics: What The Market Is Missing
Aug 19Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M
Aug 03Seres Therapeutics: The Good And The Challenging
Jul 12Seres Therapeutics stock slips on $100M stock offering
Jun 30Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?
Jun 16Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens
Jun 09Seres Therapeutics Is Playing A Long Game
Mar 06Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt
Dec 27Seres Therapeutics Molecular Data On SER-109 Looks Good
Oct 04Seres Therapeutics: Here We Go Again
Sep 09Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?
Sep 03Need To Know: Analysts Are Much More Bullish On Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenues
Jul 03Seres Therapeutics (MCRB) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow
Jun 08Seres Therapeutics gets FDA clearance for SER-155 IND trials
Jun 01Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher
May 20Seres Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 05Is Seres Therapeutics (NASDAQ:MCRB) Using Debt In A Risky Way?
Apr 05Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if MCRB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MCRB's dividend payments have been increasing.
Dividend Yield vs Market
| Seres Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (MCRB) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Biotechs) | 2.8% |
| Analyst forecast in 3 Years (MCRB) | 0% |
Notable Dividend: Unable to evaluate MCRB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MCRB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate MCRB's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MCRB has not reported any payouts.